In this InvestorIntel interview, Chris Thompson talks to Cardiol Therapeutics Inc.’s (NASDAQ: CRDL | TSX: CRDL) CEO, President and Director David Elsley about Cardiol’s therapies for the treatment of heart diseases. Currently targeting recurrent pericarditis and acute myocarditis, David discusses how these two forms of heart diseases generally affect younger populations who are otherwise healthy.
David tell Chris that there is no currently no FDA-approved therapy on the market for acute myocarditis, and only one FDA approved treatment for recurrent pericarditis which “costs upwards of $200,000 per patient per year.” Currently in Phase II clinical trials, David discusses how Cardiol is developing CardiolRx™ as an “orphan drug” for the treatment of acute myocarditis and recurrent pericarditis. He tells Chris that the current global Phase II trial is “the largest clinical program ever to be undertaken in acute myocarditis.” He goes on to provide an update on Cardiol’s new formulation in the pipeline for the treatment of heart failure.
To access the full InvestorIntel interview, click here.
Don’t miss other InvestorIntel interviews. Subscribe to the InvestorIntel YouTube channel by clicking here.
About Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The Company’s lead product candidate, CardiolRx™ (cannabidiol), is a pharmaceutically manufactured oral solution formulation that is being clinically developed for use in heart diseases. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the “ARCHER” trial) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age; and (ii) a Phase II multi-center open-label pilot study in recurrent pericarditis (inflammation of the pericardium), which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations.
Cardiol is also developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
To learn more about Cardiol Therapeutics Inc., click here
Disclaimer: Cardiol Therapeutics Inc. is an advertorial member of InvestorIntel Corp.
This interview, which was produced by InvestorIntel Corp., (IIC), does not contain, nor does it purport to contain, a summary of all the material information concerning the “Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete.
This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.
Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.
If you have any questions surrounding the content of this interview, please contact us at +1 416 792 8228 and/or email us direct at [email protected].